The Kappa-Opiate Receptor Impacts the Pathophysiology and Behavior of Substance Use

REFERENCES

• Kreek M J. Cocaine, dopamine, and the endogenous opioid system. J Addict Dis 1996; 15: 73–96
   PubMed Web of Science ®Google Scholar
• Spangler R, Zhou Y, Maggos C E, Zlobin A, Ho A, Kreek M J. Dopamine antagonists and “bing” cocaine effects on rat opioid and dopamine transporter mRNAs. NeuroReport 1996; 7: 2196–2200
   Google Scholar
• Sivam S P. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. J Pharmacol Exp Ther 1989; 250: 818–824
   PubMed Web of Science ®Google Scholar
• Smiley P L, Johnson M, Bush L, Gibb J W, Hanson G R. Effects of cocaine on extrapyramidal and limbic dynorphin systems. Pharmacology 1990; 253: 938–943
   Google Scholar
• Shippenberg T S, Zapata A, Chefer V I. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 2007; 116: 306–321
   PubMed Web of Science ®Google Scholar
• Bhargava H N, Gulati A, Ramarao P. Binding characteristics of 3HSCH 23390 in spinal cord and discrete brain regions of κ-opiate tolerant-dependent and abstinent rats. Pharmacology 1991; 42: 121–127
   Google Scholar
• Yoshimoto K, McBride W J, Lumeng L, Li T K. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 1991; 9: 17–22
   Web of Science ®Google Scholar
• Gulya K, Orpana A K, Sikela J M, Hoffman P L. Prodynorphin and vasopressin mRNA levels are differentially affected by chronic ethanol ingestion in the mouse. Brain Res Mol Brain Res 1993; 20: 1–8
   Google Scholar
• Lindholm S, Ploj K, Franck J, Nylander I. Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brains. Alcohol 2000; 22: 165–171
   PubMed Web of Science ®Google Scholar
• Zapata A, Shippenberg T S. Endogenous K-opioid receptor systems modulate the responsiveness of mesoaccumbal dopamine neurons to ethanol. Alcohol Clin Exp Res 2006; 30: 592–597
   Google Scholar
• Doyon W M, Howard E C, Shippenberg T S, Gonzales R A. K-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration. Neuropharmacol 2006; 51: 487–496
   Google Scholar
• Todtenkopf M S, Marcus J F, Portoghese P S, Carlezon W A. Effects of k-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 2004; 172: 463–470
   PubMed Web of Science ®Google Scholar
• Carlezon W A, Jr., Duman R S, Nestler E J. The many faces of CREB. TRENDS in Neurosciences 2005; 28: 436–445
   PubMed Web of Science ®Google Scholar
• Simonin F, Valverde O, Smadja C, et al. Disruption of the κ-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998; 117: 886–897
   Google Scholar
• Wang Z, Gardell L R, Ossipov M H, et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 2001; 21: 1779–1786
   PubMedGoogle Scholar
• Newton S S, Thome J, Wallace T L, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 2002; 24: 10883–10890
   Google Scholar
• Ukai M, Suzuki M, Mamiya T. Effects of U-50,488H, a κ-opioid receptor agonist, on the learned helplessness model of depression in mice. J Neural Transm 2002; 109: 1221–1225
   Google Scholar
• Gaveriaux-Ruff C, Kieffer B L. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002; 36: 62–71
   PubMed Web of Science ®Google Scholar
• Vortherms T A, Roth B L. Salvinorin A: from natural product to human therapeutics. Mol Interv 2006; 6: 257–265
   PubMed Web of Science ®Google Scholar
• Bruchas M R, Land B B, Aita M, et al. Stress-induced p38 mitogen-activated protein kinase activation mediates κ-opioid-dependent dysphoria. J Neurosci 2007; 27: 11614–11623
   Google Scholar
• Mague S D, Pliakas A M, Todtenkopf M S, et al. Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003; 305: 323–330
   PubMed Web of Science ®Google Scholar
• McLaughlin J P, Marton-Popvici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003; 23: 5674–5683
   PubMed Web of Science ®Google Scholar
• Beardsley P M, Howard J L, Shelton K L, Carroll F I. Differential effects of the novel κ-opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by foot shock stressors vs. cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 2005; 183: 118–126
   PubMed Web of Science ®Google Scholar
• Reindl J D, Rowan K, Carey A N, Peng X, Neumeyer J L, McLaughlin J P. Antidepressant-like effects of the novel κ-opioid antagonist MCL-144B in the forced-swim test. Pharmacology 2008; 81: 229–235
   Google Scholar
• Carlezon W A, Jr., Thome J, Olson V G, et al. Regulation of cocaine reward by CREB. Science 1998; 282: 2272–2275
   PubMed Web of Science ®Google Scholar
• Negus S S, Mello N K, Portoghese P S, Lin C. Effects of κ-opioids on cocaine self-adnministration by Rhesus Monkeys. J Pharmacol Exp Ther 1997; 282: 44–55
   PubMed Web of Science ®Google Scholar
• Hurd Y L, Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993; 13: 357–369
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274–5278
   PubMed Web of Science ®Google Scholar
• Acquas E, Di Chiara G. Depression of mesolimbic dopamine transmission and Sensitization to Morphine During Opiate Abstinence. J Neurochem 1992; 58: 1620–1625
   PubMed Web of Science ®Google Scholar
• Zimmer A, Valjent E, Konig M, et al. Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice”. J Neurosci 2001; 21: 9499–9505
   PubMedGoogle Scholar
• Ghozland S, Matthes H WD, Simonin F, Filliol D, Kieffer B, Maldonado R. Motivational effects of cannabinoids are mediated by κ-opioid and κ-opioid receptors. J Neurosci 2002; 22: 1146–1154
   Google Scholar
• Mitchell J M, Liang M T, Fields H L. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacology 2005; 182: 284–392
   Google Scholar
• Walker B M, Koob G F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008; 33: 643–652
   PubMed Web of Science ®Google Scholar
• Rothman R B, Gorelick D A, Heishman S J, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000; 18: 277–281
   PubMed Web of Science ®Google Scholar
• Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006; 20: 806–814
   PubMed Web of Science ®Google Scholar
• Negus S S, Dykstra L A. Kappa antagonist properties of buprenorphine in the shock titration procedure. Euro J Pharmacol 1988; 156: 77–86
   PubMed Web of Science ®Google Scholar
• Leander J D. Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice. Euro J Pharmacol 1988; 151: 457–461
   PubMed Web of Science ®Google Scholar
• Romero D V, Partilla J S, Zheng Q, et al. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay. Synapse 1999; 34: 83–94
   Google Scholar
• Giordano A L, Nock B, Cicero T J. Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu, and delta opioid receptors. J Pharmacol Exp Ther 1990; 255: 536–540
   PubMed Web of Science ®Google Scholar
• Kumar V, Guo D, Marella M, et al. Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the k opioid receptor. Bioorganic & Molecular Chemistry Letters 2008; 18: 3667–3671
   Google Scholar
• Mello N K, Lukas S E, Mendelson J H, Drieze J. Naltrexone-buprenorphine interactions: effects on cocaine self-administration. Neuropsychopharmacology 1993; 9: 211–224
   Google Scholar
• Bortolato M, Solbrig M V. The price of seizure control: dynorphins in interictal and postictal psychosis. Psychiatry Res 2007; 151: 139–143
   PubMed Web of Science ®Google Scholar
• Pfeiffer A, Brantl V, Herz A, Emrich H M. Psychotomimesis mediated by kappa opiate receptors. Science 1986; 233: 774–776
   PubMed Web of Science ®Google Scholar
• Walsh S L, Strain E C, Abreu M E, Bigelow G E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacol 2001; 157: 151–162
   PubMed Web of Science ®Google Scholar
• Bortolato M, Ary G N, Frau R, et al. Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats. Biological Psychiatry 2005; 57: 1550–1558
   Google Scholar
• Roth B L, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci 2002; 99: 11934–11939
   PubMed Web of Science ®Google Scholar
• Peters G R, Ward N J, Antal E G, Lai P Y, deMaar E W. Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther 1987; 240: 128–131
   PubMed Web of Science ®Google Scholar
• Pfeiffer A, Knepel W, Braun S, Meyer H D, Lohman H, Brantl V. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. Horm Metab Res 1986; 18: 842–848
   Google Scholar
• Reece P A, Sedman A J, Rose S, Wright D S, Dawkins R, Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 1994; 34: 1126–1132
   PubMed Web of Science ®Google Scholar
• Qi W, Ebenezar K, Samhan M A, Smith F G. Renal responses to the k-opioid receptor agonist U-50488H in conscious lambs. Am J Physiol Regul Integr Comp Physiol 2007; 293: 162–168
   Google Scholar
• Suzuki T, Mori T, Tsuji M, et al. Differential effects of μ-, δ -, and κ-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats. Euro J Pharmacol 1997; 324: 21–29
   Google Scholar
• Hasebe K, Kawai K, Suzuki T, et al. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann NY Acad Sci 2004; 1025: 404–413
   PubMedGoogle Scholar
• Walsh S L, Geter-Douglas B, Strain E C, Bigelow G E. Enadoline and Butorphanol: Evaluation of k-agonists on cocaine pharmacodynamics and cocaine self-administration. J Pharmacol Exp Ther 2001; 299: 147–158
   PubMed Web of Science ®Google Scholar
• Cohen B M, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharm 2008; 11: 243–247
   PubMed Web of Science ®Google Scholar
• Levin F R, Hennessy G. Bipolar disorder and substance abuse. Biol Psychiatry 2004; 56: 738–748
   PubMed Web of Science ®Google Scholar
• Regier D A, Farmer M E, Rae D S, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–2518
   PubMed Web of Science ®Google Scholar
• Lindholm S, Werme M, Brene S, Franck J. The selective κ-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res 2001; 120: 137–146
   Google Scholar
• Holter S M, Henniger M SH, Lipkowski A W, Spannagel R. Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats. Psychopharmacol 2000; 153: 93–102
   Google Scholar
• McCann D J. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin Pharmacol Ther 2008; 83: 627–630
   PubMed Web of Science ®Google Scholar